Log In
BCIQ
Print this Print this
 

ND003

  Manage Alerts
Collapse Summary General Information
Company Numab AG
DescriptionBispecific antibody fragment targeting interleukin-5 (IL-5) receptor and CD3
Molecular Target Interleukin-5 (IL-5) receptor ; CD3
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentDiscovery
Standard IndicationAsthma
Indication DetailsTreat asthma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$5.6M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/19/2011

Undisclosed

$5.6M

Undisclosed

Get a free BioCentury trial today